The landscape of cellular and gene therapy (CGT) manufacturing has shifted from isolated lot-release testing toward quality risk management. With the issuance of the FDA’s final guidance, Potency Assurance for Cellular and Gene Therapy Products, regulators have updated the 2011 release-testing framework to emphasize a lifecycle strategy. For regulatory affairs and CMC professionals, this document frames potency as a risk mitigation framework integrated across product development. Meeting these expectations involves connecting process design, raw material characterization, and progressive assay qualification to a product’s mechanism of action. Inadequate potency assurance strategies early in development can increase the risk of clinical holds for investigational INDs and review delays for BLAs. Overall, the guidance provides regulatory teams with recommendations for managing biological variability to support product consistency.
At the heart of the FDA’s guidance is the core concept of a Potency Assurance Strategy—a multifaceted approach designed to ensure every released product lot possesses the specific capacity to achieve its intended therapeutic effect. Grounded in Quality Risk Management (QRM) principles (such as ICH Q9(R1) and Q10), the framework spans manufacturing process design, strict material controls, in-process monitoring, and release bioassays. Regulators must establish a Quality Target Product Profile (QTPP) and identify potency-related Critical Quality Attributes (CQAs) that tie back to the mechanism of action (MOA). Because cellular starting materials and biological viral vectors inherently exhibit high variability, the agency highlights that release testing alone cannot guarantee potency. Instead, process parameters must be characterized early, and adaptive manufacturing steps should be designed to compensate for raw material fluctuations.
The guidance outlines a clear requirement for progressive implementation across the drug development lifecycle. In early-phase INDs (CTD Modules 2 and 3), sponsors are expected to define preliminary CQAs, submit risk assessments, and establish fit-for-purpose characterization assays. As clinical investigations advance into Phase 2 and Phase 3, the level of potency assurance must proportionately increase. The FDA explicitly cautions that Phase 2 or 3 trials administered with product lots of unknown or inadequately controlled potency face potential clinical holds, as sub-potent lots compromise both patient safety and the trial’s ability to generate substantial evidence of effectiveness. By the BLA submission stage, all analytical procedures used for lot release and in-process controls must be fully validated under CGMP standards (21 CFR 211.165(e)). For expedited programs on compressed development timelines, the agency strongly advises developing, qualifying, and evaluating multiple candidate assays early and in parallel to prevent post-phase regulatory delays.
Recognizing the technical complexities of advanced biologics, the FDA provides specific analytical strategies tailored to different product modalities. For cellular therapies, at least one release assay should typically be a bioassay measuring a relevant biological activity, calibrated against an qualified in-house reference standard. For viral vector gene therapies intended for direct administration, early release testing must quantitate transgene expression or enzymatic activity alongside vector particle structural integrity. Patient-specific autologous therapies and vector-transduced cell products require dual-tier controls: releasing both the upstream vector lot and the final drug product through validated quantitative bioassays. Furthermore, for short-shelf-life or non-cryopreserved products where full bioassay execution is impossible prior to lot release, sponsors may utilize real-time physicochemical surrogate assays for release while initiating post-release bioassays to support continued process verification.
Successfully adopting this regulatory guidance requires regulatory and CMC leaders to initiate early, iterative dialogue with the FDA’s Center for Biologics Evaluation and Research (CBER). By engaging CBER through formal pre-IND meetings and targeted IND amendments, sponsors can validate their QRM risk matrices, justify alternative testing approaches, and refine acceptance criteria before entering pivotal trials. Regulatory professionals should view potency assurance not as an isolated compliance burden, but as an essential strategic tool that safeguards clinical trial integrity and streamlines commercial submission pipelines. Aligning internal development programs with these expectations minimizes technical risk, prevents avoidable clinical holds, and elevates overall product quality. Ultimately, establishing a science-driven, risk-based potency assurance strategy provides the fastest and safest pathway to bringing life-changing cell and gene therapies to waiting patients.
